Renub Research

Adult Vaccines Market to be USD 20 Billion by 2022

Press release   •   Jul 21, 2017 01:50 EDT

Adult Vaccines Market is projected to be US$ 20 Billion by the year 2022. Vaccines can prevent the death rate from diseases like Pneumococcal and Influenza related complications in the adults. National Immunization Programme has been introduced by almost all the countries of the world in their vaccination schedule to overcome the epidemics caused by Vaccine preventable diseases. Global Immunization Vision and Strategy (GIVS), WHO’s Global Vaccine Action Plan, to minimize the occurrences of vaccine preventable diseases, the GAVI associations are putting their best efforts.

Adult Vaccines consists of biological products used to enhance the immune response of a body to protect against diseases like Influenza and Pneumococcal vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines, Zoster, Meningococcal, Tdap and MMRV. The adult vaccines market is driven by many factors as the occurrence of diseases, increasing government and non-government accounts for the development of vaccines as well as investments by companies. High potential growth and rising markets and development of therapeutic and adjuvant vaccines have opened opportunities for the adult vaccines market market. However, the growth of global vaccines markets is hampering by huge capital investments and stringent regulations.

Influenza Vaccines Dominates the Adult Vaccines Market

Influenza vaccine dominates the adult vaccines market in the year 2017. Globally almost all the countries, recommends the influenza vaccine to be taken annually due to increasing awareness and efficiency of the vaccine in preventing diseases. Influenza vaccine holds the maximum share into the adult vaccines market. However, it will lose its control to the Pneumococcal vaccine in the coming years. Other than Influenza and Pneumococcal vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines, Zoster, Meningococcal, Tdap and MMRV also have substantial market share in Adult Vaccines Market until the year 2022.

The Report Studies the Adult Vaccines Market on the basis of:
Vaccines Market (2011 – 2022)

1. Influenza Vaccines
2. Cervical Cancer Vaccines
3. Zoster (Shingles) Vaccines
4. MMRV (Measles, Mumps, Rubella and Varicella) Vaccines
5. Pneumonia Vaccines
6. Meningitis Vaccines
7. Hepatitis Vaccines
8. DTap (Diphtheria, Tetanus, Pertussis) Vaccines
9. Travel & Miscellaneous Vaccine

Key Players (2011 – 2022)

1. GlaxoSmithKline, plc
2. Merck & Co.
3. Sanofi Pasteur’s
4. Pfizer, Inc.’s 

Download full Report:

Contact Us

Rajat Gupta

Sr. Marketing Manager


Phone: +1-678-302-0700


Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.